igf-1 lr3
IGF-1 LR3, explained.
IGF-1 LR3 is a long-acting, engineered analog of the body's own IGF-1 that is frequently discussed in muscle-and-performance contexts. This page is a neutral overview of what it is, how it works at the molecular level, and where it sits from a regulatory standpoint.
Educational only — not medical advice. PepEasy never recommends a dose.
IGF-1 LR3 (Long R3 IGF-1) is a modified, long-acting form of insulin-like growth factor 1 — the hormone through which growth hormone drives most of its anabolic effects. Engineered to escape the binding proteins that regulate natural IGF-1, it stays active far longer. It is sold as a research reagent, is not FDA-approved for human use, and has no human trials.
What IGF-1 LR3 is
IGF-1 LR3, short for 'Long R3 IGF-1,' is a recombinant, lab-engineered version of human insulin-like growth factor 1 (IGF-1). Natural IGF-1 is a 70-amino-acid protein that carries out most of growth hormone's muscle-building signals, but the body keeps it on a tight leash: a family of IGF binding proteins (IGFBPs) locks up most of it so only a small fraction is ever active. LR3 is built to slip past that control. Two changes do the work — a 13-amino-acid extension added to one end of the molecule (the 'Long' part) and a single swap where arginine replaces glutamate at position 3 (the 'R3' part). The result is an 83-amino-acid analog that binds IGFBPs far more weakly, so much more of it circulates free and active. It was originally developed as a cell-culture supplement to make cultured cells more productive, and that is still how it is legally sold today: as a research and laboratory reagent, not a medicine. There are no human clinical trials behind its performance reputation.
How IGF-1 LR3 works
IGF-1 LR3 acts directly on the IGF-1 receptor (IGF-1R), a tyrosine-kinase receptor found on muscle, bone, fat, and many other cell types. Switching that receptor on lights up two main signaling routes. The first, the PI3K/Akt/mTOR pathway, ramps up protein synthesis, activates muscle satellite cells, and blunts breakdown — the biology behind the muscle-growth research interest. The second, the MAPK/ERK pathway, pushes cells to proliferate and differentiate. What sets LR3 apart is staying power: because the engineered changes cut its affinity for IGFBP-3 by roughly 100-fold, far less of it gets bound and cleared, giving a long half-life of about 20–30 hours and roughly three times the potency of native IGF-1 in laboratory measures. It also sits downstream of the entire growth-hormone axis — where peptides like sermorelin or CJC-1295 coax the body to make its own GH (which then raises IGF-1), LR3 supplies the active growth factor directly. One caveat worth knowing: at higher exposure it can spill over onto insulin receptors, which is why low blood sugar is a documented concern in the literature.
Areas of research interest
- Muscle growth and hypertrophy — the most-studied area, backed by mechanistic and animal data but no human trials
- Cell-culture productivity — its actual validated, established use as a laboratory reagent
- Recovery and nutrient partitioning — extrapolated from IGF-1 biology; anecdotal, not established
- Local or 'site' signaling for targeted growth — discussed in bodybuilding circles with no controlled human data
- The GH-to-IGF-1 axis — how supplying IGF-1 directly differs from stimulating the body's own growth hormone
Safety & legal status
The most immediate hazard described in the literature is hypoglycemia — IGF-1 and insulin-receptor activity can drop blood sugar, sometimes sharply — and the central long-term concern is growth signaling: chronic IGF-1R activation drives cell proliferation, carrying a theoretical, poorly-studied tumor-promotion risk, alongside possible tissue or organ growth, water retention, and headaches. There is no human safety data for performance use, so 'few reported effects' reflects an absence of study, not proven safety, and because it is sold as a research reagent, identity and purity vary widely. None of this is medical advice; consult a qualified, licensed provider. IGF-1 LR3 is not FDA-approved for human use, is sold legally only as a research/laboratory reagent, and is explicitly banned in sport by WADA.
IGF-1 LR3 vs related options
| IGF-1 LR3 | Sermorelin / CJC-1295 | Follistatin | |
|---|---|---|---|
| How it acts | Supplies active IGF-1 directly via the IGF-1 receptor | Stimulate the body's own GH, which then raises IGF-1 | Blocks myostatin to release the brake on muscle |
| Feedback control | Bypasses the GH axis — no feedback buffer | Works with normal GH feedback intact | Different mechanism entirely; not growth-factor signaling |
| Position in the axis | Downstream — the active growth factor itself | Upstream — secretagogues that drive GH release | Separate muscle-growth pathway |
| Approval status | Research-only; not FDA-approved | Not FDA-approved for performance use | Research-only; not FDA-approved |
| Defining trait | Long-acting (~20–30 h) and ~3× potency vs native IGF-1 | Indirect, feedback-preserving GH boost | Myostatin inhibition rather than receptor agonism |
How PepEasy helps
Learn it
Get clear, cited, evidence-graded answers about IGF-1 LR3 — what it is, how IGFBP evasion and IGF-1R signaling actually work, what the animal data shows, and how it sits relative to GH secretagogues like sermorelin and CJC-1295.
Understand the science
Explore the published mechanism and the GH-to-IGF-1 axis through neutral, referenced explainers — context, not instructions.
Frequently asked
What are IGF-1 LR3's side effects?+
The most immediate is hypoglycemia (low blood sugar), which can be sharp. Longer-term concerns center on growth signaling — chronic IGF-1 receptor activation drives cell proliferation, with a theoretical, under-studied tumor-promotion risk — plus possible tissue growth, water retention, and headaches. There is no human safety data for performance use.
What does the research on IGF-1 LR3 show?+
Research interest centers on muscle protein synthesis and hypertrophy, supported by mechanistic and animal data but no human trials. Its only validated, established use is as a cell-culture reagent. Recovery and local-growth observations are anecdotal and unstudied in people, so these remain open research questions rather than established findings.
Is IGF-1 LR3 a steroid?+
No, it is not an anabolic steroid — it is a modified protein that activates the IGF-1 receptor, the same receptor the body's own IGF-1 uses. It carries documented risks: hypoglycemia acutely and growth-signaling concerns long-term, with no human safety studies for performance use. This is not medical advice; consult a qualified clinician.
Is IGF-1 LR3 FDA approved?+
No. IGF-1 LR3 is not FDA-approved for human use. It is sold legally only as a research and laboratory reagent, not for administration to people, and IGF-1 analogs are explicitly banned in sport by WADA.
Everything peptides, made easy.
Join PepEasy and get the tools, the knowledge, and the care — in one place.
Explore more